SAMVEC-10 INJECTION

Indications

• Adjunct to general anesthesia
• Facilitation of tracheal intubation
• Muscle relaxation during surgery
• Mechanical ventilation

Dosage

Children: Refer to BNF for Children for specific paediatric dosing guidelines.

Adults: Initial dose of 0.08 to 0.1 mg/kg IV, with maintenance doses of 0.01 to 0.05 mg/kg IV as needed based on clinical response.

Mechanism of action

Vecuronium is a bisquaternary nitrogen compound that acts by competitively binding to nicotinic cholinergic receptors. The binding of vecuronium decreases the opportunity for acetylcholine to bind to the nicotinic receptor at the postjunctional membrane of the myoneural junction. As a result, depolarization is prevented, calcium ions are not released and muscle contraction does not occur.

Pharmacodynamics

The principal pharmacologic effects demonstrated by vecuronium revolve around its competitive binding of cholinergic receptors located at motor end plates. This competitive binding results in muscle relaxant effects that are typically employed as an adjunct to general anesthesia.

Pharmacokinetics

Vecuronium is administered intravenously and has a rapid onset of action, typically within 2 to 3 minutes. The drug is metabolized by the liver and eliminated primarily through the liver and kidneys. The duration of action is dose-dependent, and its effects can be reversed with anticholinesterase agents like neostigmine.

Contra-indications

• Hypersensitivity to vecuronium or any component of the formulation
• Myasthenia gravis
• Severe electrolyte disturbances

Adverse effects

• Respiratory depression
• Prolonged neuromuscular block
• Hypotension
• Tachycardia
• Allergic reactions

Interactions

• Aminoglycosides may potentiate the effects of vecuronium.
• Calcium channel blockers may enhance neuromuscular blockade.
• Anticonvulsants may reduce the neuromuscular blocking effect.

Precautions

• Use with caution in patients with neuromuscular disorders.
• Monitor respiratory function and neuromuscular effects in patients undergoing surgery.
• Adjust dosage in patients with hepatic or renal impairment.

Pregnancy

Vecuronium should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

Caution is advised when administering vecuronium to breastfeeding mothers, as it is not known whether it is excreted in human milk.

Storage

Store in a cool, dry place, protected from light. Keep out of reach of children.

Formulations

• Injection solution

Indications

• Neuromuscular blockade during surgery
• Facilitation of tracheal intubation
• Neuromuscular blockade in intensive care settings

Dosage

Children: Refer to the BNF for Children for paediatric dosing guidelines.

Adults: Initially by intravenous injection: 80–100 micrograms/kg; maintenance dose is adjusted according to response, typically 0.8–1.4 micrograms/kg/minute.

Mechanism of action

Vecuronium bromide competitively antagonizes nicotinic acetylcholine receptors at the neuromuscular junction, preventing acetylcholine from binding and thus inhibiting muscle contraction. This results in neuromuscular blockade, which is reversible with acetylcholinesterase inhibitors.

Pharmacodynamics

The onset of action for vecuronium bromide is typically within 2 to 3 minutes, with peak neuromuscular blockade occurring around 3 to 5 minutes after administration. The duration of action can vary depending on the dose and individual patient factors, lasting from 30 to 60 minutes. Recovery from blockade usually begins within 20 to 30 minutes.

Pharmacokinetics

Vecuronium bromide is administered intravenously and is subject to hepatic and renal metabolism. Its clearance is primarily hepatic, with a half-life of approximately 40 to 60 minutes. In patients with hepatic impairment, the duration of neuromuscular blockade may be prolonged due to reduced clearance. Renal impairment can also affect the duration of action, necessitating careful monitoring and potential dose adjustments.

Contra-indications

• Known hypersensitivity to vecuronium bromide or any of its excipients
• Myasthenia gravis
• Severe neuromuscular disease
• Conditions where neuromuscular blockade is contraindicated

Adverse effects

• Hypotension
• Bradycardia
• Respiratory depression
• Prolonged neuromuscular blockade
• Allergic reactions
• Malignant hyperthermia

Interactions

• Other neuromuscular blocking agents may enhance the effect
• General anesthetics may potentiate neuromuscular blockade
• Antibiotics (especially aminoglycosides) may potentiate the effects
• Magnesium salts may enhance neuromuscular block

Precautions

• Caution in patients with cardiovascular disease
• Use with caution in hepatic impairment
• Use with caution in renal impairment
• Monitor respiratory function closely during administration

Pregnancy

Vecuronium bromide is generally not recommended during pregnancy unless the benefits outweigh the risks. It is a category C drug.

Breast-feeding

It is not known whether vecuronium bromide is excreted in human breast milk. Caution should be exercised when it is administered to a nursing woman.

Storage

Store in a cool, dry place. Protect from light. Once opened, use promptly as per local guidelines.

Formulations

• Solution for injection 10 mg/10 ml
• Solution for injection 20 mg/10 ml

Mechanism of action

Vecuronium is a bisquaternary nitrogen compound that acts by competitively binding to nicotinic cholinergic receptors. The binding of vecuronium decreases the opportunity for acetylcholine to bind to the nicotinic receptor at the postjunctional membrane of the myoneural junction. As a result, depolarization is prevented, calcium ions are not released and muscle contraction does not occur.

Pharmacodynamics

The principal pharmacologic effects demonstrated by vecuronium revolve around its competitive binding of cholinergic receptors located at motor end plates. This competitive binding results in muscle relaxant effects that are typically employed as an adjunct to general anesthesia.